GlobeNewswire · Press release
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records
Event records load after the price chart.
Healthcare · Biotechnology
The Quantellect read. PYPD rose 0.31% in the Nov 18 session to $6.56, which is 0.6% below its 52-week high of $6.60. Short interest is 3.60% of float with a 5.99% borrow fee. One active firm covers the stock as of Nov 19, 2026; one active firm with a target averages $13.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.
—
RSI (14) 59.6 (overbought above 70, oversold below 30)
—
FINRA settlement Oct 30, 2026
Price $6.56 · As of Nov 18, 2026, 3:59 PM ET
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records load after the price chart.
| Range | 6M |
|---|---|
| First close | — |
| Last close | — |
| High | — |
| Low | — |
| Volume | — |
PYPD · nasdaq · USD
Last completed session: Nov 18, 2026
Split-adjusted · volume in shares
— · Notable price movement not available
— · Options flow not available
Insufficient data · Tide session Nov 18, 2026
— · Industry comparison not available
Insufficient coverage
Based on 1 active firms as of Nov 19, 2026 (365-day activity window)
As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
GlobeNewswire · Press release
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.